My watch list  

At ImevaX, short for „immune evasion vaccines“, we developed a vaccine against Helicobacter pylori. This pathogen has a unique mechanism to inhibit the immune system, enabling Helicobacter pylori to infect life-long.Our vaccine uses this mechanism against the pathogen. It disables the bacterial factor that inhibits the immune response. The result: the immune system can recognize, combat and eliminate the bacterium. Starting in January 2017, the lead product IMX101 and the mucosal adjuvant are tested in a clinical phase I trial. With this, we at ImevaX validate two antigens and one novel mucosal adjuvant.Furthermore, a novel mucosal adjuvant and a Helicobacter pylori rapid diagnostic test are currently developed at ImevaX.

More about ImevaX
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE